Go to content
UR Home

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, Ulrich, Macdonald, D. R., Forsyth, P., Rossetti, A. O., Lacombe, D., Mirimanoff, R.-O., Vecht, C. J. and Stupp, R. (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77 (12), pp. 1156-1164.

Full text not available from this repository.

at PubMed

at publisher (via DOI)


Abstract

VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.


Export bibliographical data



Item type:Article
Date:2011
Institutions:Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Hirntumore (ZHT)
Identification Number:
ValueType
11300327PubMed ID
10.1212/WNL.0b013e31822f02e1DOI
Classification:
NotationType
AdolescentMESH
AdultMESH
AgedMESH
Antineoplastic Agents, Alkylating/therapeutic useMESH
Brain Neoplasms/mortalityMESH
Canada/epidemiologyMESH
Dacarbazine/therapeutic useMESH
Europe/epidemiologyMESH
FemaleMESH
Glioblastoma/mortalityMESH
HumansMESH
MaleMESH
Middle AgedMESH
Retrospective StudiesMESH
Survival Rate/trendsMESH
Valproic Acid/therapeutic useMESH
Young AdultMESH
Dewey Decimal Classification:600 Technology > 610 Medical sciences Medicine
Status:Published
Refereed:Yes, this version has been refereed
Created at the University of Regensburg:Unknown
Item ID:29190
Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons